The U.S. Food and Drug Administration cleared expanded use of GlaxoSmithKline Plc’s Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy.
As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.
GRAIL published validation data for the company’s multi-cancer early detection blood test, which can detect more than 50 different cancer types across all stages.
Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.
Researchers at the University of Pennsylvania School of Medicine found that certain changes in DNA sequences can trigger the resulting genome to misfold in such a way that the person is at increased risk for Type 1 diabetes.
Novacyt says the Franco-British biotech company can offer a coronavirus test that is faster than rival methods by focusing on a narrow sequence of DNA coding.
As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.
Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.
Many people worry about inheriting health problems from their parents, but a new approach to analyzing genetic contributions to disease risk suggests that for most diseases, commercial DNA tests are not the best way to assess the odds.
Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.
